IP Library Granted Patent US 10,385,381
Granted Patent B2
US 10,385,381 · App. 13/825,047 · Granted Aug 20, 2019

Serum preparation

Inventors: Paul Masci (St. Lucia, AU); John De Jersey (St. Lucia, AU); Martin Lavin (St. Lucia, AU); Julie Phillips (St. Lucia, AU); Goce Dimeski (Hamilton, AU)
C12Q1/56G01N33/86
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,385,381
App. No.
13/825,047
Granted
Aug 20, 2019
Kind
B2
Abstract

This invention relates to the use of clotting compositions containing prothrombin activators to produce high quality blood serum samples for pathology and other biological assays, and to containers containing such clotting compositions, and related methods of use.

Claims (11)

1. A serum preparation container, the container comprising a puncturable septum or cap and being evacuated for drawing blood from a subject into the container, and containing an amount of a surfactant and an amount of a blood clotting composition for preparing a serum sample suitable for detecting an analyte, wherein the blood clotting composition consists essentially of a recombinantly-produced snake venom prothrombin activator, wherein the snake venom prothrombin activator is functional to activate prothrombin without a mammalian factor Xa polypeptide.

2. A method of preparing a serum sample for detecting an analyte of interest, the method comprising collecting a blood sample in a blood collection container, said blood collection container comprising a puncturable septum or cap and being evacuated for drawing blood from a subject into the container, and containing an amount of a surfactant and an amount of a blood clotting composition for preparing a serum sample suitable for detecting an analyte, wherein the blood clotting composition consists essentially of a recombinantly-produced snake venom prothrombin activator that is functional to activate prothrombin without a mammalian factor Xa polypeptide, contacting the blood sample with the blood clotting composition in the container for a time and under conditions sufficient to prepare the serum sample.

3. A method of detecting an analyte of interest, the method comprising providing a serum sample prepared by a serum preparation method and analysing the serum sample for the presence or amount of the analyte of interest, wherein the serum preparation method comprises collecting a blood sample in a blood collection container, said blood collection container comprising a puncturable septum or cap and being evacuated for drawing blood from a subject into the container, and containing an amount of a surfactant and an amount of a blood clotting composition for preparing a serum sample suitable for detecting an analyte, wherein the blood clotting composition consists essentially of a recombinantly-produced purified snake venom prothrombin activator that is functional to activate prothrombin without a mammalian factor Xa polypeptide, contacting the blood sample with the blood clotting composition in the container for a time and under conditions sufficient to prepare the serum sample.

4. The serum preparation container according to claim 1 , wherein the snake venom prothrombin activator is a group A prothrombin activator.

5. The serum preparation container according to claim 4 , wherein the snake venom prothrombin activator is selected from ecarin and basparin.

6. The serum preparation container according to claim 1 , wherein the snake venom prothrombin activator is a group B prothrombin activator.

7. The serum preparation container according to claim 6 , wherein the snake venom prothrombin activator is selected from carinactivase-1, carinactivase-2 and multactivase.

8. The serum preparation container according to claim 1 , wherein the snake venom prothrombin activator is a group C prothrombin activator.

9. The serum preparation container according to claim 8 , wherein the snake venom prothrombin activator is selected from pseutarin C, oscutarin C and Omicarin C.

10. The serum preparation container according to claim 1 , wherein the snake venom prothrombin activator is a group D prothrombin activator.

11. The serum preparation container according to claim 10 , wherein the snake venom prothrombin activator is selected from porpharin D, notecarin D, trocarin D, hopsarin D and notenarin D.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2017
From: DIMESKI, GOCE
To: THE STATE OF QUEENSLAND ACTING THROUGH QUEENSLAND HEALTH; THE UNIVERSITY OF QUEENSLAND
Reel/Frame 043966/0486 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2017
From: THE STATE OF QUEENSLAND ACTING THROUGH QUEENSLAND HEALTH
To: THE UNIVERSITY OF QUEENSLAND
Reel/Frame 043966/0528 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2017
From: THE UNIVERSITY OF QUEENSLAND
To: UNIQUEST PTY LIMITED
Reel/Frame 043967/0519 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2017
From: UNIQUEST PTY LIMITED
To: Q-SERA PTY LTD
Reel/Frame 043967/0558 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2013
From: MASCI, PAUL; DE JERSEY, JOHN; LAVIN, MARTIN; PHILLIPS, JULIE
To: THE UNIVERSITY OF QUEENSLAND
Reel/Frame 030659/0391 →
Priority Claims (1)
AU 2010904233 · Sep 20, 2010 · national
Continuity (1)
Related Publication 20130273584A1 · Oct 17, 2013